PMID-18561511 – Pramlintide Physiology Pathophysiology and Vascular Risk
Ryan GJ, Jobe LJ, Martin R. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008;4(2):355-362.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18561511 |
| DOI | 10.2147/VHRM.S1978 |
| Year | 2008 |
| Journal | Vascular Health and Risk Management |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of published clinical data |
| Peptide(s) Studied | Pramlintide |
Key Findings
- Amylin is co-secreted with insulin from pancreatic beta cells in a ~1:100 amylin:insulin ratio
- In T1D, amylin is virtually absent; in T2D, amylin secretion is deficient relative to demand
- Pramlintide mimics three key amylin actions: (1) slowing gastric emptying, (2) suppressing postprandial glucagon secretion, (3) promoting satiety via area postrema signaling
- Pramlintide complements insulin by regulating the rate of glucose appearance into circulation after meals
- Vascular risk biomarkers (triglycerides, oxidative stress markers) showed improvements with pramlintide
- The amylin/pramlintide pathway is mechanistically distinct from the GLP-1 incretin pathway
- Pramlintide's satiety effect is mediated centrally through the area postrema and hypothalamus
Study Design
Comprehensive narrative review covering amylin physiology, the development of pramlintide as a synthetic amylin analog, its clinical pharmacology, and its effects on glycemic control, body weight, and cardiovascular risk biomarkers. Draws from preclinical data and published clinical trials.
Limitations
- Narrative review (not systematic); potential selection bias in cited studies
- Published in 2008, before long-term safety data and many comparator trials
- Limited discussion of combination therapy approaches
- No quantitative synthesis of data
Clinical Relevance
This review provides a foundational understanding of the amylin pathway and its therapeutic exploitation through pramlintide. The three-pronged mechanism (gastric emptying, glucagon suppression, central satiety) is distinct from and complementary to GLP-1 agonism. This mechanistic independence is the scientific basis for combining amylin analogs (cagrilintide) with GLP-1 RAs (semaglutide) in CagriSema, which targets two independent satiety/glucose pathways simultaneously. Practitioners must understand this distinction to properly educate patients on why amylin-pathway agents add value beyond GLP-1 RAs alone.
Related
#research #narrative-review #evidence-level-V #metabolic #pramlintide